铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌感染合并活动性胃溃疡的临床观察

Clinical Observation of Hydrotalcite Tablets Plus Esomeprazole Enteric-coated Tablets in Helicobacter Pylori Infection Patients with Active Gastric Ulcer

目的:探究铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌感染合并活动性胃溃疡的临床效果.方法:对笔者所在医院2018年2月-2019年2月收治的80例幽门螺杆菌感染合并活动性胃溃疡患者展开对照研究,所有患者均采取常规三联疗法,在此基础上将其随机分为联合治疗组(铝碳酸镁片联合埃索美拉唑肠溶片治疗)与单纯用药组(埃索美拉唑肠溶片治疗)各40例,探讨实施不同治疗对治疗效果的影响.结果:两组总有效率对比,观察组(97.50%)显著比对照组(85.00%)高(P<0.05),两组治疗前的C反应蛋白(CRP)差异无统计学意义(P>0.05),治疗2、4周后观察组CRP显著比对照组低(P<0.05),两组不良反发生率对比,观察组(12.50%)与对照组(7.50%)差异无统计学意义(P>0.05).结论:在常规三联疗法基础上将铝碳酸镁片联合埃索美拉唑肠溶片应用于幽门螺杆菌感染合并活动性胃溃疡患者时,可显著提升疗效,改善炎性因子,且不良反应小,患者可耐受,此方法值得应用与推广.

Objective:To observe the clinical effects of Hydrotalcite Tablets plus Esomeprazole Enteric-coated Tablets in helicobacter pylori infection patients with active gastric ulcer.Method:A total of 80 helicobacter pylori infection patients with active gastric ulcer of taking triple therapy from February 2018 to February 2019 were investigated and randomly assigned to the combined group(n=40,Hydrotalcite Tablets plus Esomeprazole Enteric-coated Tablets)and the single group(n=40,Esomeprazole Enteric-coated Tablets).The therapeutic effect was discussed.Result:The total effective rate in the combined group(97.50%)was significantly higher than that of single group(85.00%),with significant difference(P<0.05);before treatment,C-reactive protein(CRP)levels between groups were not significantly different(P>0.05);after 2W and 4W of treatment,CRP levels in the combined group were significantly lower than those of the single group(P<0.05);the adverse event rate in the combined group and single group was 12.50%and 7.50%,there was no significant difference(P>0.05).Conclusion:Based on triple therapy,Hydrotalcite Tablets combined with Esomeprazole Enteric-coated Tablets in helicobacter pylori patients with active gastric ulcer can remarkably reduce the adverse reactions,and improve the curative effect,inflammatory factors and drug tolerance.It is worthy of clinical application and promotion.